<DOC>
	<DOCNO>NCT02774473</DOCNO>
	<brief_summary>Patients history metastatic breast cancer candidate participation companion therapeutic trial , UPCC 06115 `` A Phase I Trial Ribociclib ( LEE011 ) Weekly Paclitaxel Patients Rb+ Advanced Breast Cancer '' may candidate image study . Patients may participate study least 18 year age , participant receive care clinical practice University Pennsylvania . Patients meet eligibility criterion approach study participation regardless race ethnic background . The investigator anticipate enrol 20 participant metastatic breast cancer meet eligibility requirement study companion therapy trial UPCC 06115 `` A Phase I Trial Ribociclib ( LEE011 ) Weekly Paclitaxel Patients Rb+ Advanced Breast Cancer '' , Accrual likely occur approximately 4 year . Positron emission tomography ( PET/CT ) image use evaluate proliferative activity sit metastatic disease use investigational radiotracer [ 18F ] fluorothymidine ( FLT ) . Imaging occur prior start therapy separate therapeutic protocol UPCC 06115 . Patients may undergo second FLT PET/CT scan follow 3-day run ribociclib ( LEE011 ) ( day -6 -4 ) Day -3 ( Â± 1 day ) third FLT PET/CT scan cycle 1 day 1 ( -1 day ) start treatment Paclitaxel compare change FLT uptake measure .</brief_summary>
	<brief_title>18FFluorothymidine ( FLT ) PET/CT Imaging In Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 And Weekly Paclitaxel Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>At least 18 year age History histologically cytologically confirm breast cancer , ER , PR HER2 status allow long express Rb protein . At least one site metastatic breast cancer outside liver bone identify standard imaging ( e.g . CT , MRI , FDG PET/CT , ultrasound , xray ) measurable define RECIST 1.1 Participants must inform investigational nature study provide write informed consent accordance institutional federal guideline prior studyspecific procedure . Patients must candidate receive treatment therapeutic trial UPCC06115 , Phase I study ribociclib ( LEE011 ) weekly paclitaxel . Females pregnant time screen eligible study , urine pregnancy test perform screen woman childbearing potential . Inability tolerate image procedure opinion investigator treat physician Serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation study . Ineligible therapeutic trial UPCC 06115 Only individual ( age 18 ) understand give inform consent eligible participate study . Individuals consider mentally disabled recruit study . All subject must able give informed consent . We use specific method assess decisional capacity . Economically disadvantaged person vulnerable undue influence , patient informed participation voluntary . All individual tell choice regard study participation way change access clinical care . This negate undue influence coercion . Children , fetuses , neonate , prisoner include research study . It unlikely researcher encounter patient/study participant pregnant enrollment pregnant patient may enroll parent treatment protocol , UPCC06115 . However , menopausal status study participant review screen process examine patient 's medical record ; woman childbearing potential urine pregnancy test time screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Rb+</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>